What we are studying
You are invited to join voluntarily in a clinical research study to find out if the drugs INCB024360 and MEDI4736 (Study Drugs) are safe and have beneficial effects when given together in people who have selected types of cancer. INCB024360 is an investigational drug that is being developed by Incyte Corporation (the Sponsor of this research Study) for the treatment of selected types of cancer. MEDI4736 is an investigational drug that is being developed by Medimmune as a treatment for advanced cancer. “Investigational” means that the drug has not been approved by US Food and Drug Administration (FDA) for general use as a prescription or over-the-counter medication. INCB024360 and MEDI4736 are both treatments designed to help your immune system (the part of your body that fights infections and cancer). By making your immune system more active, we hope to help your body fight your cancer. These drugs both help your immune system but they work in different ways. INCB024360 is a chemical drug that stops a protein (also called an enzyme) in your body called indoleamine-2,3-dioxygenase-1 (IDO1). This protein plays a role in blocking your immune system. MEDI4736 is designed to improve the immune system’s ability to recognize and destroy cancer cells by targeting a protein in your body called Programmed death ligand 1 (PD-L1). In cancer, immunotherapies are increasingly being investigated or used to boost the body’s immune system so that cancer cells are recognized and destroyed. We hope these treatments result in the cancer shrinking and the person being treated living longer.